Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

NCT04068974 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Platinum-resistant Ovarian Cancer

Interventions

DRUG: Camrelizumab (SHR-1210)
DRUG: Apatinib

Sponsor

Peking Union Medical College Hospital